Scientific Publications

Title	Date	Category	Status	Publication URL
Atriva Therapeutics announces publication of Proof of Concept (POC) / Phase 2a RESPIRE study data with zapnometinib in patients hospitalized with COVID-19	2023-10-04	Scientific Publication	publish	Read more
MEK inhibition with zapnometinib as a treatment for RNA virus infections: The dual benefit of host immunomodulation and antiviral activity	2023-09-18	Scientific Publication	publish	Read more
Establishment of a novel method to assess MEK1/2 inhibition in PBMCs for clinical drug development	2022-12-12	Scientific Publication	publish	Read more
Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats	2022-12-05	Scientific Publication	publish	Read more
The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs	2022-08-25	Scientific Publication	publish	Read more
Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans	2022-06-15	Scientific Publication	publish	Read more
The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses	2022-01-10	Scientific Publication	publish	Read more
Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002	2021-02-12	Scientific Publication	publish	Read more
Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model	2020-06-01	Scientific Publication	publish	Read more